How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes.

Yiqi Qian, Wei Wu, Minmin Wang, Yifan Wei, Ming Zhong

Abstract readLetter

In one paragraph

Article in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yiqi QianDepartment of Critical Care Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, 200032, Shanghai, China.

Wei WuDepartment of Critical Care Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, 200032, Shanghai, China.

Minmin WangBaxter Healthcare Corporation, Deerfield, IL, US.

Yifan WeiBaxter Healthcare Corporation, Deerfield, IL, US.

Ming ZhongDepartment of Critical Care Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, 200032, Shanghai, China. zhong.ming@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We are writing to you in response to the article published in BMC Nephrology titled "Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study". The study provided valuable information on the use of nafamostat mesylate (NM) during continuous renal replacement therapy (CRRT) in critically ill patients. We noticed in this study that a higher dose of NM resulted in a decrease in ICU and hospital mortality. However, the underlying mechanism behind this phenomenon remains unclear. We believe exploring this further is warranted.

Indexed as

BenzamidinesCritical IllnessGuanidinesAcute Kidney InjuryAdsorptionContinuous Renal Replacement TherapyHumansMembranes, ArtificialRenal Replacement TherapyBenzamidinesGuanidinesMembranes, ArtificialnafamostatAdsorptionContinuous renal replacement therapyFilter membraneNafamostat mesylate

Identifiers

PMID39304801

DOI10.1186/s12882-024-03745-1

PMCPMC11414190

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.